Skip to content

Welcome to Discover Pharma! Today is : November 2, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

OPERA cohort

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Cabenuva real-world study reports sustained HIV viral suppression

    A US observational study of nearly 7,000 adults with HIV-1 [...]

    October 23, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    ViiV’s Cabenuva shows superior HIV control to daily oral therapy in adolescents

    ViiV Healthcare’s long-acting injectable Cabenuva has demonstrated superior virologic outcomes [...]

    July 30, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • SalubrisBio reports JK06 results across three cancer types
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Tango reports 82% response rate in pancreatic cancer trial
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • FDA seeks input on new rare disease drug development framework
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top